We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Alnylam Pharmaceuticals Inc (ALNY) Com Stk USD0.01

Sell:$244.76 Buy:$244.87 Change: $1.91 (0.77%)
NASDAQ:0.16%
Market closed |  Prices as at close on 22 November 2024 | Switch to live prices |
Sell:$244.76
Buy:$244.87
Change: $1.91 (0.77%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 22 November 2024 | Switch to live prices |
Sell:$244.76
Buy:$244.87
Change: $1.91 (0.77%)
Market closed |  Prices as at close on 22 November 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. In addition, the Company develops Cemdisiran to treat complement-mediated diseases, Belcesiran for the treatment of alpha-1 liver disease, Elebsiran, Zilebesiran, ALN-APP, ALN-HSD, Fitusiran, and others.

Contact details

Address:
675 W Kendall St
CAMBRIDGE
02142-1168
United States
Telephone:
+1 (617) 5518200
Website:
https://www.alnylam.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
ALNY
ISIN:
US02043Q1076
Market cap:
$32.09 billion
Shares in issue:
128.98 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Yvonne Greenstreet
    Chief Executive Officer, Director
  • Jeffrey Poulton
    Chief Financial Officer, Executive Vice President
  • Kevin Fitzgerald
    Executive Vice President, Chief Scientific Officer, Head - Early Research and Early Development
  • Pushkal Garg
    Chief Medical Officer, Executive Vice President - Development and Medical Affairs
  • Michael Bonney
    Chief Compliance Officer, Director
  • Tolga Tanguler
    Chief Commercial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.